Women newly diagnosed with ovarian cancer (N = 16) and women from the community (N = 17) each described 3 early memories. We assessed the developmental maturity level of the memories with Mayman's Libidinal Level of Relationships scale, which assesses the maturity of memories form oral to latency levels. The early memories of the cancer patients were at a significantly lower libidinal level and more often involved oral relationship themes than the memories of the community women. The results suggest that a diagnosis of a life-threatening illness can invoke comforting memories of being cared for and fed, associated with a greater sense of dependence on others.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/NMD.0b013e31819cb208 | DOI Listing |
Acta Neuropathol
January 2025
Department of Neurology, NYU Grossman School of Medicine, New York, NY, USA.
Down syndrome (DS) is strongly associated with Alzheimer's disease (AD) due to APP overexpression, exhibiting Amyloid-β (Aβ) and Tau pathology similar to early-onset (EOAD) and late-onset AD (LOAD). We evaluated the Aβ plaque proteome of DS, EOAD, and LOAD using unbiased localized proteomics on post-mortem paraffin-embedded tissues from four cohorts (n = 20/group): DS (59.8 ± 4.
View Article and Find Full Text PDFAust N Z J Psychiatry
January 2025
Neuropsychiatry Centre, The Royal Melbourne Hospital, Parkville, VIC, Australia.
Introduction: Young-onset neurocognitive symptoms result from a heterogeneous group of neurological and psychiatric disorders which present a diagnostic challenge. To identify such factors, we analysed the Biomarkers in Younger-Onset Neurocognitive Disorders cohort, a study of individuals <65 years old presenting with neurocognitive symptoms for a diagnosis and who have undergone cognitive and biomarker analyses.
Methods: Sixty-five participants (median age at assessment of 56 years, 45% female) were recruited during their index presentation to the Royal Melbourne Hospital Neuropsychiatry Centre, a tertiary specialist service in Melbourne, Australia, and categorized as either early-onset Alzheimer's disease ( = 18), non-Alzheimer's disease neurodegeneration ( = 23) or primary psychiatric disorders ( = 24).
BMC Psychol
January 2025
Beijing Key Laboratory of Applied Experimental Psychology, Faculty of Psychology, National Demonstration Center for Experimental Psychology Education (Beijing Normal University), Beijing Normal University, Beijing, 100875, China.
An ongoing debate on the association between phonological processing and number knowledge concerns the extent to which they influence each other during early childhood. The current study aims to establish the direction of the developmental relationship between these two kinds of abilities at an early age. Eighty-two Chinese kindergarten children were followed from 5 to 6 years old with a one-year interval.
View Article and Find Full Text PDFJ Prev Alzheimers Dis
January 2025
Department of Psychiatry, Faculty of Medicine Ramathibodi Hospital Mahidol University, 270 Rama VI Rd., Ratchathewi, Bangkok, 10400, Thailand.
Background: Older adults with mild behavioral impairment (MBI) are at the higher risk of developing dementia compared to those without MBI, leading to decreased quality of life (QoL). Addressing MBI in older adults provides valuable opportunities to prevent dementia.
Objectives: This study aimed to determine the effects of traditional Thai folk dance combined with a cognitive stimulation program on MBI, QoL, subjective cognitive decline (SCD), and cognitive functioning in older Thai adults.
J Immunother Cancer
January 2025
Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Purpose: BMS-986299 is a first-in-class, NOD-, LRR-, and pyrin-domain containing-3 (NLRP3) inflammasome agonist enhancing adaptive immune and T-cell memory responses.
Materials And Methods: This was a phase-I (NCT03444753) study that assessed the safety and tolerability of intra-tumoral BMS-986299 monotherapy (part 1A) and in combination (part 1B) with nivolumab, and ipilimumab in advanced solid tumors. Reported here are single-center results.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!